meta
|
evidence
oncology
Living systematic review and meta-analysis
breast cancer - triple negative
es-BC - Triple negatif (TNBC) - (neo)adjuvant (NA)
es-BC - TNBC - NA - all population
5
es-BC - TNBC - NA - PDL1 positive
1
es-BC - Triple negatif (TNBC) - 1st line (L1)
mBC - Triple negative (TNBC) - (neo)adjuvant (NA)
mBC - Triple negative (TNBC) - 1st Line (L1)
1
mBC - TNBC - L1 - all population
7
mBC - TNBC - L1 - PDL1 positive
4
mBC-Triple negative (TNBC) - 2nd Line (L2)
3
mBC - TNBC - L2 - all population
2
mBC - TNBC - L2 - PDL1 positive
2
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab plus carboplatin plus nab-paclitaxel
atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide
durvalumab based treatment
durvalumab alone
pembrolizumab based treatment
pembrolizumab alone
poly ADP-ribose polymerase (PARP) inhibitor
olaparib
versus all
vs chemotherapy
vs platinum-based chemotherapy
vs platinum derivate
vs platinum association
vs paclitaxel plus carboplatin
vs carboplatin plus nab-paclitaxel
vs Standard of Care (SoC)
vs placebo plus SoC
vs non active control
vs placebo
All patients
PD-L1 < 1%
PD-L1 > 1%
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
button
bars
forest
bayes
pooled
summary
circles
deaths (OS) (extension)
pCR
AE leading to death (grade 5)
SAE (any grade)
hepatitis (Autoimmune) AE (grade 3-4)
Abdominal pain AE (grade 3-4)
Alopecia AE (grade 3-4)
Anaemia AE (grade 3-4)
Arthralgia AE (grade 3-4)
Back pain AE (grade 3-4)
Blood creatinine increased AE (grade 3-4)
Constipation AE (grade 3-4)
Cough AE (grade 3-4)
Diarrhoea AE (grade 3-4)
Dry skin AE (grade 3-4)
Dyspnoea AE (grade 3-4)
Epistaxis AE (grade 3-4)
Fatigue AE (grade 3-4)
Febrile neutropenia AE (grade 3-4)
Headache AE (grade 3-4)
Hyperthyroidism AE (grade 3-4)
Hypophysitis AE (grade 3-4)
Hypothyroidism AE (grade 3-4)
Increase AST AE (grade 3-4)
Increased ALT AE (grade 3-4)
Infusion-related reaction AE (grade 3-4)
Injury, poisoning and procedure AE (grade 3-4)
Leucopenia AE (grade 3-4)
Myalgia AE (grade 3-4)
Nausea AE (grade 3-4)
Neutropenia AE (grade 3-4)
Peripheral neuropathy AE (grade 3-4)
Pneumonitis AE (grade 3-4)
Rash AE (grade 3-4)
Stomatitis AE (grade 3-4)
Thrombocytopenia AE (grade 3-4)
Vomiting AE (grade 3-4)
deaths (OS) (extension)
es-BC - TNBC - NA - all population
breast cancer - triple negative
es-BC - Triple negatif (TNBC) - (neo)adjuvant (NA)
es-BC - TNBC - NA - all population
versus placebo
durvalumab alone vs. placebo
1
0.24
×
delta: difference in rate or median (if available)
×
Extraction panel open
An extraction panel is open